Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "We are very pleased to have had the opportunity to present these latest data for SparVax(TM) at Annual Conference on Vaccine Research. The study, which compared our vaccine to the currently licensed anthrax vaccine, BioThrax(R), provides further confirmation that SparVax(TM) is immunogenic and promotes good immunological recall following antigenic challenge. In addition, a lower incidence of injection site reactions observed with SparVax(TM) may suggest that it is better tolerated than BioThrax(R), a very important finding for this product candidate. Presentation of these data to attendees at this conference allows PharmAthene to continue to increase awareness of the progress we are making developing improved products using modern vaccine technologies to protect our Nation's citizens and military."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene.

The study was one of two Phase II trials evaluating different dose and dosing regimens of Sp
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... Durham, NC (PRWEB) October 24, 2014 ... appears to overcome several pitfalls of current skin grafting ... scarring and produces hair. The method, outlined in the ... a breakthrough for treating deep skin injuries that result ... skin injury completely destroys the skin’s regenerative elements. These ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)... Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the ... the Fourth International Symposium on Thymosins in Health and ... "When thymosin beta 4 (TB4) linked with ... peritoneal cavity in a rodent model of stroke, it ... brain parenchyma (the functional tissue of the brain).   The ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... Wash., June 16, 2011 SCOLR Pharma, Inc. (OTC: ... of $1 million principal amount of its 8% Senior ... initial closing of its private offering of up to ... offer additional Debentures, up to the aggregate maximum of ...
... KNDL ), a leading, global full-service ... senior clinical development experts will present on important ... 47th Annual Meeting, June 19-23, 2011, in Chicago. ... benefits of hybrid monitoring; finding an economic balance ...
... 2011 MacuCLEAR, Inc., a specialty clinical stage pharmaceutical ... vascular disorders of the eye, announced today that Philip ... OneMedForum New York 2011 on Thursday, June 23, 2011 ... New York City.   OneMedForum will focus ...
Cached Biology Technology:SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 3Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C. 2
(Date:10/19/2014)... Improving household electricity access in India over the ... nation,s total carbon emissions growth during that time, ... journal Nature Climate Change ., "Energy access ... all aspects of life, including education, communication, and ... the study. , While increased energy access is ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... found a way of stimulating the immune systems ... the devastating plaques,that are characteristic of Alzheimer's disease.,For ... a,protein-based vaccine to slow the progression of the ... created a gene-based,vaccine aimed at stimulating the immune ...
... cells',responsible for hearing and balance. Traditionally viewed as ... for the normal development,of nerve cells responsible for ... research. The study is reported in the January ... scientists at the University,of Washington.,"Using zebrafish as a ...
... essential for 'hair cells',responsible for hearing and balance. ... may be essential for the normal development,of nerve ... new,University of Utah research. The study is reported ... is co-authored by scientists at the University,of Washington.,"Using ...
Cached Biology News:Gene vaccine for Alzheimer's disease shows promising results 2GenMAPP 2.0 released 2Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined 2
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... macroporous polystyrene beads for hydrophobic interaction chromatography. ... adsorbing organics of molecular weight less than ... useful for the adsorption of nonpolar substances ... removal of detergents such as Triton X-100 ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
... Phospho-Specific(Thr 222 ) ... 10 mM sodium HEPES, 100 ... 7.5. Recognizes the ~47 kDa ... (MAPKAPK-2) protein phosphorylated at Thr ...
Biology Products: